Maribavir for stubborn CMV after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether taking maribavir for different lengths of time can help treat a stubborn CMV infection after a stem cell transplant. It is for people whose CMV hasn't improved with standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had your first stem cell transplant from a donor (allogeneic) and are at least 18 years old.
- You have a CMV infection that is not getting better with standard antiviral treatment (refractory).
- You do not have active hepatitis B, HIV, or severe organ failure (like severe heart, lung, liver, or kidney problems).
- You are not allergic to maribavir or any of its ingredients.
- You do not have CMV in your brain or spinal cord, and you are able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This study tests a medicine called maribavir for people who have a CMV infection after a stem cell transplant. It watches how well the medicine works and how safe it is.
This study looks at the medication maribavir for people who have a CMV infection after a transplant that is not getting better with current treatments. The goal is to see how well maribavir works in this situation.
This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.
This study tests a new medicine called maribavir for Chinese adults who have a CMV infection that hasn't gotten better with standard treatments. It may be an option for transplant recipients who need a different approach.
This trial tests a new drug, maribavir, for controlling or treating active CMV infection in people with certain blood cancers (multiple myeloma, follicular lymphoma, or large B-cell lymphoma) who are taking a bispecific antibody therapy. The goal is to see if maribavir is safe and effective for managing CMV in this specific situation.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.